Madrigal Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Co.'s primary product candidate, resmetirom, is being developed as a once-daily oral pill to treat several disease states, including non-alcoholic steatohepatitis, or NASH. Co. has initiated MAESTRO-NASH, a Phase 3 trial in NASH with its once daily, oral thyroid hormone receptor beta selective agonist, resmetirom. Co. has opened for enrollment MAESTRO-NAFLD-1, a Phase 3 clinical study of patients with biopsy-confirmed or presumed NASH recruited from sites in the U.S. We show 31 historical shares outstanding datapoints in our MDGL shares outstanding history coverage, used to compute MDGL market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing MDGL market cap history over the course of time is important for investors
interested in comparing MDGL's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of MDGL versus a peer is one thing; comparing
MDGL market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like MDGL can fluctuate over the course of history.
With this page we aim to empower investors researching MDGL by allowing them to research the MDGL market cap history. |
Free MDGL Email Alerts:
Video: The Importance of Market Cap
